Source:http://linkedlifedata.com/resource/pubmed/id/18590933
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2008-11-17
|
pubmed:abstractText |
Older age is an independent predictor of mortality after percutaneous coronary intervention (PCI) in patients with Non-ST elevation Acute Coronary Syndrome (ACS). GPIIb/IIIa inhibitors are proved to improve outcome in high risk patients, but conflicting data are available about the effects of these inhibitors in elderly. Accordingly, we studied a consecutive population of elderly patients undergoing PCI for Non-ST elevation ACS. A total of 500 patients were divided in: GPI group (247 pts; mean age 77+/-1.9 years) treated by stenting plus abciximab and, no GPI group (253 pts; mean age 77+/-2.4 years) treated by stenting alone. Propensity analysis was used to account for the nonrandomized use of GPIIb/IIIa inhibitors. During hospitalization, incidence of death was similar among groups (3.2% vs 4.6%) without difference regarding incidence of major (1.6% vs 1.1%) and minor bleedings (4% vs 3%). At long-term follow-up the rate of death was significantly lower in GPI group (4.5% vs 12.3%; p=0.002) as well as the rate of acute myocardial infarction (2.8% vs 11.1%; p=0.0001), and pre-PCI (5.7% vs 13.4%; p=0.003). Cox regression analysis identified abciximab use as an independent predictor of lower long-term major adverse cardiac event (MACE) after adjustment for propensity score (Exp (B) 0.620, 95%CI 0.394-0.976, p=0.039). Our results suggest that addition of abciximab to stenting improves outcome in elderly patients with Non-ST elevation ACS, leading to an absolute benefit for reduction of death and MACE, with an acceptable rate of major and minor bleedings.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Glycoprotein GPIIb-IIIa...,
http://linkedlifedata.com/resource/pubmed/chemical/abciximab
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1874-1754
|
pubmed:author |
pubmed-author:ChiarielloMassimoM,
pubmed-author:CirilloPlinioP,
pubmed-author:EspositoGiovanniG,
pubmed-author:FurbattoFulvioF,
pubmed-author:GalassoGennaroG,
pubmed-author:LeoscoDarioD,
pubmed-author:PierriAdeleA,
pubmed-author:PiscioneFedericoF,
pubmed-author:RapacciuoloAntonioA,
pubmed-author:RosaRoberta DeRD
|
pubmed:issnType |
Electronic
|
pubmed:day |
28
|
pubmed:volume |
130
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
380-5
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:18590933-Acute Coronary Syndrome,
pubmed-meshheading:18590933-Aged,
pubmed-meshheading:18590933-Angioplasty, Balloon, Coronary,
pubmed-meshheading:18590933-Antibodies, Monoclonal,
pubmed-meshheading:18590933-Combined Modality Therapy,
pubmed-meshheading:18590933-Disease-Free Survival,
pubmed-meshheading:18590933-Female,
pubmed-meshheading:18590933-Follow-Up Studies,
pubmed-meshheading:18590933-Hemorrhage,
pubmed-meshheading:18590933-Humans,
pubmed-meshheading:18590933-Immunoglobulin Fab Fragments,
pubmed-meshheading:18590933-Male,
pubmed-meshheading:18590933-Platelet Aggregation Inhibitors,
pubmed-meshheading:18590933-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:18590933-Risk Factors,
pubmed-meshheading:18590933-Treatment Outcome
|
pubmed:year |
2008
|
pubmed:articleTitle |
Abciximab in elderly with acute coronary syndrome invasively treated: effect on outcome.
|
pubmed:affiliation |
Division of Cardiology, Federico II University, Naples, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|